MX2009008511A - Reduccion de efectos secundarios de tramadol. - Google Patents
Reduccion de efectos secundarios de tramadol.Info
- Publication number
- MX2009008511A MX2009008511A MX2009008511A MX2009008511A MX2009008511A MX 2009008511 A MX2009008511 A MX 2009008511A MX 2009008511 A MX2009008511 A MX 2009008511A MX 2009008511 A MX2009008511 A MX 2009008511A MX 2009008511 A MX2009008511 A MX 2009008511A
- Authority
- MX
- Mexico
- Prior art keywords
- tramadol
- side effects
- phosphodiesterase inhibitor
- tramadol material
- reducing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
La presente invención proporciona métodos para reducir los efectos secundarios de tramadol. Por consiguiente, en una modalidad, la presente invención proporciona un método para reducir la incidencia de los efectos secundarios recientemente descubiertos, relacionados con la función sexual en hombres humanos que toman un material de tramadol. El método comprende administrar un inhibidor de fosfodiesterasa a un hombre que toma el material de tramadol. La presente invención también proporciona composiciones farmacéuticas. En una modalidad, la composición comprende un material de tramadol y un inhibidor de fosfodiesterasa. La presente invención proporciona además equipos. En una modalidad, el equipo comprende un material de tramadol y un inhibidor de fosfodiesterasa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88938007P | 2007-02-12 | 2007-02-12 | |
PCT/US2008/053722 WO2008100933A2 (en) | 2007-02-12 | 2008-02-12 | Reducing side effects of tramadol |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009008511A true MX2009008511A (es) | 2010-01-20 |
Family
ID=39690762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009008511A MX2009008511A (es) | 2007-02-12 | 2008-02-12 | Reduccion de efectos secundarios de tramadol. |
Country Status (17)
Country | Link |
---|---|
US (3) | US20080261991A1 (es) |
EP (2) | EP2486921A1 (es) |
JP (1) | JP5550101B2 (es) |
KR (2) | KR101497509B1 (es) |
CN (1) | CN101674728A (es) |
AU (1) | AU2008216363B2 (es) |
BR (1) | BRPI0807281A2 (es) |
CA (1) | CA2677691C (es) |
DK (1) | DK2114147T3 (es) |
ES (1) | ES2384127T3 (es) |
HK (1) | HK1131730A1 (es) |
MX (1) | MX2009008511A (es) |
NZ (1) | NZ579170A (es) |
PL (1) | PL2114147T3 (es) |
SG (1) | SG178775A1 (es) |
WO (1) | WO2008100933A2 (es) |
ZA (1) | ZA200906187B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ579170A (en) * | 2007-02-12 | 2012-05-25 | Dmi Biosciences Inc | Reducing side effects of tramadol |
US20080262094A1 (en) * | 2007-02-12 | 2008-10-23 | Dmi Biosciences, Inc. | Treatment of Comorbid Premature Ejaculation and Erectile Dysfunction |
US8202525B2 (en) | 2009-12-22 | 2012-06-19 | Pondera Biotechnologies, LLC | Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
CA2833307C (en) | 2011-04-12 | 2018-01-23 | Revogenex Inc. | Intravenous administration of tramadol |
WO2015134695A1 (en) * | 2014-03-07 | 2015-09-11 | Vyrix Pharmaceuticals, Inc. | Method of mitigating the side effects of a phosphodiesterase type v inhibitor in a subject |
US20160228485A1 (en) * | 2015-02-11 | 2016-08-11 | Latasha M. Watts | Skin medicating system |
US9980900B2 (en) | 2015-12-22 | 2018-05-29 | Revogenex Ireland Ltd | Intravenous administration of tramadol |
US9693949B1 (en) | 2015-12-22 | 2017-07-04 | Revogenex Ireland Ltd | Intravenous administration of tramadol |
US10022321B2 (en) | 2016-06-30 | 2018-07-17 | Revogenex Ireland Ltd. | Intravenous administration of tramadol |
WO2020006606A1 (en) * | 2018-07-05 | 2020-01-09 | Helium 3 Resources Pty Ltd | A pharmaceutical composition and method of use of same |
CA3187455A1 (en) * | 2020-07-29 | 2022-02-03 | Stephen Kwaku DORDUNOO | Pharmaceutical formulations comprising tadalafil |
US11504332B2 (en) * | 2021-03-23 | 2022-11-22 | Vk Research Associates Inc. | Phosphodiesterase-4 inhibitor combinations, methods of making, and methods of use thereof |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3652589A (en) | 1967-07-27 | 1972-03-28 | Gruenenthal Chemie | 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols |
US3830934A (en) * | 1967-07-27 | 1974-08-20 | Gruenenthal Chemie | Analgesic and antitussive compositions and methods |
US4127118B1 (en) | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
KR0169950B1 (ko) | 1990-04-25 | 1999-01-15 | 에드워드 엘. 멘델 | 발기 기능장애 치료용 제형, 어셈블리 및 조성물 |
US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
US5151448A (en) | 1991-07-12 | 1992-09-29 | Crenshaw Roger T | Method for treating premature ejaculation |
DK0566709T5 (da) | 1991-09-06 | 2009-05-18 | Ortho Mcneil Janssen Pharm | Præparat indeholdende et tramadolmateriale og acetaminophen og anvendelse deraf |
US5223541A (en) | 1991-09-13 | 1993-06-29 | Mcneilab, Inc. | Tramadol n-oxide material, enantiomers and compositions thereof, and their use |
US5512578A (en) * | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
US5580876A (en) * | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
USRE36547E (en) * | 1992-09-21 | 2000-02-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists |
US20010006967A1 (en) | 1992-09-21 | 2001-07-05 | Stanley M. Crain | Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists |
US6096756A (en) * | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US5472943A (en) * | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
IL119660A (en) * | 1993-05-10 | 2002-09-12 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
DE4329794C2 (de) | 1993-09-03 | 1997-09-18 | Gruenenthal Gmbh | Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung |
GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
US5861431A (en) | 1995-06-07 | 1999-01-19 | Iotek, Inc. | Incontinence treatment |
GB9514464D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
US6017963A (en) | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
DE19601745C1 (de) | 1996-01-19 | 1997-10-09 | Gruenenthal Gmbh | Verfahren zur Racematspaltung von Tramadol |
DE19601744C2 (de) * | 1996-01-19 | 1998-04-16 | Gruenenthal Gmbh | Verfahren zur Herstellung der Enantiomeren von O-Demethyltramadol |
IL119121A (en) | 1996-08-22 | 2000-11-21 | Chemagis Ltd | Process for the purification of (RR-SS)-2-dimethylaminomethyl-1-(3-methoxyphenyl)cyclohexanol hydrochloride |
US6331543B1 (en) * | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US6056968A (en) | 1997-03-11 | 2000-05-02 | Darwin Discovery Limited | Pharmaceutical drug dosage forms providing different release rates |
AU6747698A (en) * | 1997-04-11 | 1998-11-11 | Nippon Shinyaku Co. Ltd. | Remedies for frequent urination and urinary incontinence |
US6037360A (en) | 1997-10-28 | 2000-03-14 | Vivus, Incorporated | Administration of 5-HT3 receptor antagonists to treat premature ejaculation |
US6403597B1 (en) * | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
CH693954A5 (de) | 1997-11-12 | 2004-05-14 | Bayer Ag | 2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase Inhibitoren. |
US6375957B1 (en) * | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
DK1041987T3 (da) * | 1997-12-22 | 2006-08-21 | Euro Celtique Sa | Oral farmaceutisk doseringsform omfattende en kombination af en opioid-agonist og naltrexon |
HUP0100310A3 (en) * | 1997-12-22 | 2002-11-28 | Euro Celtique Sa | A method of preventing abuse of opioid dosage forms |
US6339826B2 (en) * | 1998-05-05 | 2002-01-15 | International Business Machines Corp. | Client-server system for maintaining a user desktop consistent with server application user access permissions |
GT199900061A (es) * | 1998-05-15 | 2000-10-14 | Pfizer | Formulaciones farmaceuticas. |
US6156342A (en) | 1998-05-26 | 2000-12-05 | Andex Pharmaceuticals, Inc. | Controlled release oral dosage form |
US6403605B1 (en) * | 1998-05-29 | 2002-06-11 | Queen's University At Kingston | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
US6476078B2 (en) * | 1999-08-11 | 2002-11-05 | Sepracor, Inc. | Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction |
US6339106B1 (en) * | 1999-08-11 | 2002-01-15 | Sepracor, Inc. | Methods and compositions for the treatment and prevention of sexual dysfunction |
US6331571B1 (en) * | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
HUP0104420A2 (en) | 1998-12-02 | 2002-08-28 | Darwin Discovery Ltd | Therapeutic composition containing a new form of tramadol and its use |
US6087362A (en) * | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
US6943166B1 (en) | 1999-04-30 | 2005-09-13 | Lilly Icos Llc. | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
US6765010B2 (en) | 1999-05-06 | 2004-07-20 | Pain Therapeutics, Inc. | Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
US20030055070A1 (en) * | 1999-07-01 | 2003-03-20 | Wilma Harrison | Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction |
US6821975B1 (en) | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
US6451806B2 (en) * | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
WO2001034125A2 (en) | 1999-11-09 | 2001-05-17 | Darwin Discovery Limited | Therapeutic use and formulation of (-)-tramadol |
US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
US20020091129A1 (en) * | 2000-11-20 | 2002-07-11 | Mitradev Boolell | Treatment of premature ejaculation |
AU2002252361C1 (en) * | 2001-03-16 | 2006-03-30 | Aytu Bioscience, Inc. | Method of delaying ejaculation |
DE60216078T2 (de) * | 2001-05-11 | 2007-07-05 | Endo Pharmaceuticals Inc. | Opioid enthaltende arzneiform gegen missbrauch |
MXPA04001210A (es) * | 2001-08-06 | 2004-07-08 | Euro Celtique Sa | Formulaciones de agonista opioide con antagonista liberable y aislado. |
US7019010B2 (en) * | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
CN1585771A (zh) * | 2001-11-09 | 2005-02-23 | 先灵公司 | 多环鸟嘌呤衍生物磷酸二酯酶v抑制剂 |
AU2003217669A1 (en) * | 2002-02-25 | 2003-09-09 | Smithkline Beecham Corporation | A method of recuding anti-neoplastic agent induced side effects |
US20040202717A1 (en) * | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
US20050054688A1 (en) * | 2003-08-08 | 2005-03-10 | Pfizer Inc | Selective serotonin reuptake inhibitors in the treatment of disease |
US20060149480A1 (en) * | 2004-02-26 | 2006-07-06 | Lundeen James E | Method of making combination medicament and medicament made thereby |
JP4475098B2 (ja) * | 2004-11-02 | 2010-06-09 | ソニー株式会社 | 記憶素子及びその駆動方法 |
AU2006219643A1 (en) * | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of PDE7 inhibitors for the treatment of neuropathic pain |
EP1969117A4 (en) * | 2005-12-13 | 2008-12-17 | Trinity Lab Inc | METHOD FOR TREATING EARLY EJACULATION IN HUMANS |
US20070185145A1 (en) * | 2006-02-03 | 2007-08-09 | Royds Robert B | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same |
US20080262094A1 (en) * | 2007-02-12 | 2008-10-23 | Dmi Biosciences, Inc. | Treatment of Comorbid Premature Ejaculation and Erectile Dysfunction |
NZ579170A (en) * | 2007-02-12 | 2012-05-25 | Dmi Biosciences Inc | Reducing side effects of tramadol |
WO2008131256A1 (en) * | 2007-04-19 | 2008-10-30 | Trinity Laboratories Inc. | Improved treatments for premature ejaculation in humans |
-
2008
- 2008-02-12 NZ NZ579170A patent/NZ579170A/en not_active IP Right Cessation
- 2008-02-12 AU AU2008216363A patent/AU2008216363B2/en not_active Ceased
- 2008-02-12 KR KR1020097018879A patent/KR101497509B1/ko active IP Right Grant
- 2008-02-12 SG SG2012009536A patent/SG178775A1/en unknown
- 2008-02-12 WO PCT/US2008/053722 patent/WO2008100933A2/en active Application Filing
- 2008-02-12 DK DK08729655.4T patent/DK2114147T3/da active
- 2008-02-12 EP EP12167725A patent/EP2486921A1/en not_active Withdrawn
- 2008-02-12 CN CN200880011692A patent/CN101674728A/zh active Pending
- 2008-02-12 JP JP2009549685A patent/JP5550101B2/ja not_active Expired - Fee Related
- 2008-02-12 ES ES08729655T patent/ES2384127T3/es active Active
- 2008-02-12 BR BRPI0807281-7A2A patent/BRPI0807281A2/pt not_active IP Right Cessation
- 2008-02-12 CA CA2677691A patent/CA2677691C/en not_active Expired - Fee Related
- 2008-02-12 PL PL08729655T patent/PL2114147T3/pl unknown
- 2008-02-12 US US12/029,973 patent/US20080261991A1/en not_active Abandoned
- 2008-02-12 KR KR1020137027225A patent/KR20130122023A/ko not_active Application Discontinuation
- 2008-02-12 MX MX2009008511A patent/MX2009008511A/es active IP Right Grant
- 2008-02-12 EP EP08729655.4A patent/EP2114147B9/en active Active
-
2009
- 2009-09-07 ZA ZA2009/06187A patent/ZA200906187B/en unknown
- 2009-11-18 HK HK09110782.2A patent/HK1131730A1/xx not_active IP Right Cessation
-
2011
- 2011-09-28 US US13/247,450 patent/US20120018333A1/en not_active Abandoned
-
2013
- 2013-08-19 US US13/970,198 patent/US20130338166A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2486921A1 (en) | 2012-08-15 |
EP2114147B1 (en) | 2012-05-16 |
WO2008100933A3 (en) | 2008-10-16 |
CA2677691C (en) | 2012-07-31 |
ES2384127T3 (es) | 2012-06-29 |
EP2114147B9 (en) | 2013-04-10 |
KR101497509B1 (ko) | 2015-03-03 |
HK1131730A1 (en) | 2010-02-05 |
CN101674728A (zh) | 2010-03-17 |
PL2114147T3 (pl) | 2012-10-31 |
CA2677691A1 (en) | 2008-08-21 |
US20080261991A1 (en) | 2008-10-23 |
ZA200906187B (en) | 2013-02-27 |
JP2010518168A (ja) | 2010-05-27 |
US20120018333A1 (en) | 2012-01-26 |
KR20130122023A (ko) | 2013-11-06 |
NZ579170A (en) | 2012-05-25 |
AU2008216363B2 (en) | 2014-05-08 |
AU2008216363A1 (en) | 2008-08-21 |
EP2114147A4 (en) | 2010-04-07 |
SG178775A1 (en) | 2012-03-29 |
BRPI0807281A2 (pt) | 2014-04-29 |
JP5550101B2 (ja) | 2014-07-16 |
WO2008100933A2 (en) | 2008-08-21 |
US20130338166A1 (en) | 2013-12-19 |
EP2114147A2 (en) | 2009-11-11 |
KR20090127277A (ko) | 2009-12-10 |
DK2114147T3 (da) | 2012-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009008511A (es) | Reduccion de efectos secundarios de tramadol. | |
PH12014500053A1 (en) | Proteasome inhibitors | |
TW200738263A (en) | ANG2 and VEGF inhibitor combinations | |
MY160041A (en) | Compositions and methods for treating parasitic infections | |
PH12015501191A1 (en) | Boronate ester compounds and pharmaceutical compositions thereof | |
SG164368A1 (en) | Treatment of cancer | |
TW200740803A (en) | Heterocyclic derivatives as modulators of ion channels | |
TW200618817A (en) | Diffractive colorants for cosmetics | |
NO20092637L (no) | Fremgangsmater for behandling | |
MX366925B (es) | Inhibidores de ibat para el tratamiento de enfermedades hepaticas. | |
MY166653A (en) | Derivatives of 1-amino-2-cyclobutylethylboronic acid | |
MX2010006154A (es) | Tratamiento del cancer con combinaciones de inhibidores de la topoisomerasa e inhibidores de la poli-adp-ribosa-polimerasa. | |
DE602005018043D1 (de) | Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung | |
WO2008030883A3 (en) | Treatment of cancer | |
RS52921B (en) | TREATMENT OF INFLAMMATORY DISEASES USING PLACENTAL CELL CELLS | |
MX359639B (es) | Metodos y composiciones para uso en tratamientos celulares. | |
BRPI0617294B8 (pt) | composição farmacêutica em gel hidroalcóolico e uso de testosterona | |
NO20090157L (no) | Tienpyrimidiner anvendelige som modulatorer av ionekanaler | |
EP2513343A4 (en) | METHODS AND COMPOSITIONS FOR TREATING SKIN INFLAMMATION | |
EP1962843A4 (en) | USE OF PARP-1 INHIBITORS | |
PH12014501440A1 (en) | Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction | |
UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
ZA201003352B (en) | Heterocyclic derivatives as modulators of ion channels | |
MX2009008491A (es) | Tratamiento de disfuncion erectil y eyaculacion prematura copatologicas. | |
WO2006130493A8 (en) | Heterocycles useful as modulators of ion channels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
GB | Transfer or rights |